Taysha Gene Therapies, Inc. Investing Cash Flow
Taysha Gene Therapies, Inc. (TSHA) reported Investing Cash Flow of -$3.02 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-11
- Taysha Gene Therapies, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $1.00K, a 98.39% decline year-over-year.
- Taysha Gene Therapies, Inc. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$3.02M.
- Taysha Gene Therapies, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$247.00K, a 2000.00% decline year-over-year.
- Taysha Gene Therapies, Inc. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$48.00K.
- Taysha Gene Therapies, Inc. net cash provided by (used in) investing activities for fiscal 2025 was -$604.00K.
- Taysha Gene Therapies, Inc. net cash provided by (used in) investing activities for fiscal 2024 was -$363.00K.
- Taysha Gene Therapies, Inc. net cash provided by (used in) investing activities for fiscal 2023 was -$7.35M.
- Taysha Gene Therapies, Inc. net cash provided by (used in) investing activities for fiscal 2022 was -$24.93M.
| Period end | Net Cash Provided by (Used in) Investing Activities 0 month | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$3.02M 10-Q · filed 2026-08-11 | -$3.27M derived: sum of 3 quarters · filed 2026-08-11 | -$3.32M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2026-03-31 | -$3.02M 10-Q · filed 2026-05-06 | -$3.27M derived: sum of 2 quarters · filed 2026-05-06 | -$3.32M derived: sum of 3 quarters · filed 2026-05-06 | -$3.26M derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-12-31 | -$247.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$295.00K derived: sum of 2 quarters · filed 2026-03-19 | -$233.00K derived: sum of 3 quarters · filed 2026-08-11 | -$604.00K 10-K · filed 2026-03-19 | |
| 2025-09-30 | -$48.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $14.00K derived: sum of 2 quarters · filed 2026-08-11 | -$357.00K 10-Q · filed 2025-11-04 | -$344.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-06-30 | $62.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$309.00K 10-Q · filed 2026-08-11 | -$296.00K derived: sum of 3 quarters · filed 2026-08-11 | -$331.00K derived: sum of 4 quarters · filed 2026-08-11 | |
| 2025-03-31 | -$371.00K 10-Q · filed 2026-05-06 | -$358.00K derived: sum of 2 quarters · filed 2026-05-06 | -$393.00K derived: sum of 3 quarters · filed 2026-05-06 | -$594.00K derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$22.00K derived: sum of 2 quarters · filed 2026-03-19 | -$223.00K derived: sum of 3 quarters · filed 2026-03-19 | -$363.00K 10-K · filed 2026-03-19 | |
| 2024-09-30 | -$35.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$236.00K derived: sum of 2 quarters · filed 2025-11-04 | -$376.00K 10-Q · filed 2025-11-04 | -$386.00K derived: sum of 4 quarters · filed 2025-11-04 | |
| 2024-06-30 | -$201.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$341.00K 10-Q · filed 2025-08-12 | -$351.00K derived: sum of 3 quarters · filed 2025-08-12 | -$3.84M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | -$140.00K 10-Q · filed 2025-05-15 | -$150.00K derived: sum of 2 quarters · filed 2025-05-15 | -$3.64M derived: sum of 3 quarters · filed 2025-05-15 | -$3.59M derived: sum of 4 quarters · filed 2025-05-15 | |
| 2023-12-31 | -$10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | -$3.50M derived: sum of 2 quarters · filed 2025-02-26 | -$3.45M derived: sum of 3 quarters · filed 2025-02-26 | -$7.35M 10-K · filed 2025-02-26 | |
| 2023-09-30 | -$3.49M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$3.44M derived: sum of 2 quarters · filed 2024-11-13 | -$7.34M 10-Q · filed 2024-11-13 | -$9.71M derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $48.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$3.85M 10-Q · filed 2024-08-12 | -$6.22M derived: sum of 3 quarters · filed 2024-08-12 | -$9.24M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | -$3.90M 10-Q · filed 2024-05-14 | -$6.27M derived: sum of 2 quarters · filed 2024-05-14 | -$9.29M derived: sum of 3 quarters · filed 2024-05-14 | -$17.40M derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | -$2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | -$5.39M derived: sum of 2 quarters · filed 2024-03-19 | -$13.50M derived: sum of 3 quarters · filed 2024-03-19 | -$24.93M 10-K · filed 2024-03-19 | |
| 2022-09-30 | -$3.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$11.13M derived: sum of 2 quarters · filed 2023-11-14 | -$22.56M 10-Q · filed 2023-11-14 | -$31.08M derived: sum of 4 quarters · filed 2023-11-14 | |
| 2022-06-30 | -$8.11M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$19.54M 10-Q · filed 2023-08-14 | -$28.06M derived: sum of 3 quarters · filed 2023-08-14 | -$32.06M derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | -$11.43M 10-Q · filed 2023-05-11 | -$19.95M derived: sum of 2 quarters · filed 2023-05-11 | -$23.95M derived: sum of 3 quarters · filed 2023-05-11 | -$32.45M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | -$8.52M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | -$12.52M derived: sum of 2 quarters · filed 2023-03-28 | -$21.02M derived: sum of 3 quarters · filed 2023-03-28 | -$21.55M 10-K · filed 2023-03-28 | |
| 2021-09-30 | -$4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$12.50M derived: sum of 2 quarters · filed 2022-11-08 | -$13.03M 10-Q · filed 2022-11-08 | -$19.09M derived: sum of 4 quarters · filed 2022-11-08 | |
| 2021-06-30 | -$8.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$9.03M 10-Q · filed 2022-08-11 | -$15.08M derived: sum of 3 quarters · filed 2022-08-11 | -$15.11M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | -$534.00K 10-Q · filed 2022-05-16 | -$6.58M derived: sum of 2 quarters · filed 2022-05-16 | -$6.62M derived: sum of 3 quarters · filed 2022-05-16 | -$9.62M derived: sum of 4 quarters · filed 2022-05-16 | |
| 2020-12-31 | -$6.05M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$6.08M derived: sum of 2 quarters · filed 2022-03-31 | -$9.08M derived: sum of 3 quarters · filed 2022-03-31 | -$9.08M 10-K · filed 2022-03-31 | |
| 2020-09-30 | -$31.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$3.03M derived: sum of 2 quarters · filed 2021-11-10 | -$3.03M 10-Q · filed 2021-11-10 | -$3.03M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | -$3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | -$3.00M 10-Q · filed 2021-08-16 | -$3.00M derived: sum of 3 quarters · filed 2021-08-16 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-11 | $0.00 derived: sum of 2 quarters · filed 2021-05-11 | |||
| 2019-12-31 | $0.00 10-K · filed 2021-03-03 | ||||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |